Cargando…

Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril

BACKGROUND: To evaluate cardiovascular function in boys with Duchenne (DMD) and Becker (BMD) muscular dystrophy, using cardiac magnetic resonance (CMR). METHODS: This is a single point cross sectional study of twenty-four boys with genetically ascertained DMD, and 10 with BMD, aged 10.5 ± 1.5 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Mavrogeni, Sophie, Giannakopoulou, Aikaterini, Papavasiliou, Antigoni, Markousis-Mavrogenis, George, Pons, Roser, Karanasios, Evangelos, Noutsias, Michel, Kolovou, Genovefa, Papadopoulos, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525273/
https://www.ncbi.nlm.nih.gov/pubmed/28738778
http://dx.doi.org/10.1186/s12872-017-0627-x
_version_ 1783252614313410560
author Mavrogeni, Sophie
Giannakopoulou, Aikaterini
Papavasiliou, Antigoni
Markousis-Mavrogenis, George
Pons, Roser
Karanasios, Evangelos
Noutsias, Michel
Kolovou, Genovefa
Papadopoulos, George
author_facet Mavrogeni, Sophie
Giannakopoulou, Aikaterini
Papavasiliou, Antigoni
Markousis-Mavrogenis, George
Pons, Roser
Karanasios, Evangelos
Noutsias, Michel
Kolovou, Genovefa
Papadopoulos, George
author_sort Mavrogeni, Sophie
collection PubMed
description BACKGROUND: To evaluate cardiovascular function in boys with Duchenne (DMD) and Becker (BMD) muscular dystrophy, using cardiac magnetic resonance (CMR). METHODS: This is a single point cross sectional study of twenty-four boys with genetically ascertained DMD, and 10 with BMD, aged 10.5 ± 1.5 years (range 9–13), were prospectively evaluated by a 1.5 T system and compared with those of age-sex matched controls. The DMD patients were divided in 2 groups. Group A (N = 12) were under treatment with both deflazacort and perindopril, while Group B (n = 12) were under treatment with deflazacort, only. BMD patients did not take any medication. Biventricular function was assessed using a standard SSFP sequence. Late gadolinium enhancement (LGE) was assessed from T1 images taken 15 min after injection of 0.2 mg/Kg gadolinium DTPA using a 3D–T1-TFE sequence. RESULTS: Group A and BMDs were asymptomatic with normal ECG, 24 h ECG recording and echocardiogram. Group B were asymptomatic but 6/12 had abnormal ECG and mildly impaired LVEF. Their 24 h ECG recording revealed supraventricular and ventricular extrasystoles (all at 12–13 yrs). LV indices in Group A and BMD did not differ from those of controls. However, LV indices in Group B were significantly impaired compared with controls, Group A and BMDs (p < 0.001). An epicardial LGE area = 3 ± 0.5% of LV mass was identified in the posterolateral wall of LV only in 6/12 patients of Group B, but in not in any BMD or Group A. CONCLUSION: Children with either BMD or DMD under treatment with both deflazacort and perindopril present preserved LV function and lack of LGE. However, further large scale multicenter studies are warranted to confirm these data, including further CMR mapping approaches.
format Online
Article
Text
id pubmed-5525273
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55252732017-07-26 Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril Mavrogeni, Sophie Giannakopoulou, Aikaterini Papavasiliou, Antigoni Markousis-Mavrogenis, George Pons, Roser Karanasios, Evangelos Noutsias, Michel Kolovou, Genovefa Papadopoulos, George BMC Cardiovasc Disord Research Article BACKGROUND: To evaluate cardiovascular function in boys with Duchenne (DMD) and Becker (BMD) muscular dystrophy, using cardiac magnetic resonance (CMR). METHODS: This is a single point cross sectional study of twenty-four boys with genetically ascertained DMD, and 10 with BMD, aged 10.5 ± 1.5 years (range 9–13), were prospectively evaluated by a 1.5 T system and compared with those of age-sex matched controls. The DMD patients were divided in 2 groups. Group A (N = 12) were under treatment with both deflazacort and perindopril, while Group B (n = 12) were under treatment with deflazacort, only. BMD patients did not take any medication. Biventricular function was assessed using a standard SSFP sequence. Late gadolinium enhancement (LGE) was assessed from T1 images taken 15 min after injection of 0.2 mg/Kg gadolinium DTPA using a 3D–T1-TFE sequence. RESULTS: Group A and BMDs were asymptomatic with normal ECG, 24 h ECG recording and echocardiogram. Group B were asymptomatic but 6/12 had abnormal ECG and mildly impaired LVEF. Their 24 h ECG recording revealed supraventricular and ventricular extrasystoles (all at 12–13 yrs). LV indices in Group A and BMD did not differ from those of controls. However, LV indices in Group B were significantly impaired compared with controls, Group A and BMDs (p < 0.001). An epicardial LGE area = 3 ± 0.5% of LV mass was identified in the posterolateral wall of LV only in 6/12 patients of Group B, but in not in any BMD or Group A. CONCLUSION: Children with either BMD or DMD under treatment with both deflazacort and perindopril present preserved LV function and lack of LGE. However, further large scale multicenter studies are warranted to confirm these data, including further CMR mapping approaches. BioMed Central 2017-07-24 /pmc/articles/PMC5525273/ /pubmed/28738778 http://dx.doi.org/10.1186/s12872-017-0627-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mavrogeni, Sophie
Giannakopoulou, Aikaterini
Papavasiliou, Antigoni
Markousis-Mavrogenis, George
Pons, Roser
Karanasios, Evangelos
Noutsias, Michel
Kolovou, Genovefa
Papadopoulos, George
Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril
title Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril
title_full Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril
title_fullStr Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril
title_full_unstemmed Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril
title_short Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril
title_sort cardiac profile of asymptomatic children with becker and duchenne muscular dystrophy under treatment with steroids and with/without perindopril
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525273/
https://www.ncbi.nlm.nih.gov/pubmed/28738778
http://dx.doi.org/10.1186/s12872-017-0627-x
work_keys_str_mv AT mavrogenisophie cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT giannakopoulouaikaterini cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT papavasiliouantigoni cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT markousismavrogenisgeorge cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT ponsroser cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT karanasiosevangelos cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT noutsiasmichel cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT kolovougenovefa cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril
AT papadopoulosgeorge cardiacprofileofasymptomaticchildrenwithbeckerandduchennemusculardystrophyundertreatmentwithsteroidsandwithwithoutperindopril